Retatrutide in Tennessee: Trial-registry Status and Research Records
At a glance
- Review question / What do federal sources and ClinicalTrials.gov records establish about retatrutide in Tennessee?
- Best evidence / federal status and trial-registry records
- Evidence snapshot / 2026-08-09
- Commercial status / no FDA-approved product or ordinary retail supply
- HealthRX role / independent educational review; no retatrutide product or treatment offer
Direct answer
Retatrutide is not commercially available in the state. In the 2026-08-09 ClinicalTrials.gov snapshot, 10 retatrutide study records listed at least one location in Tennessee. Example identifiers were NCT04881760, NCT05929066, NCT06297603. A location listing can describe a completed, active, or planned site; it does not establish current recruitment, eligibility, public supply, or commercial availability.
The wording here is deliberately evidence-specific. “A study exists,” “a registry lists a site,” and “a paper reports an endpoint” are different statements from “a product is approved,” “a treatment works,” or “a person should use it.” This page makes only the first type of statement and links the controlling source.
Evidence map for trial-registry status in Tennessee
| Primary source | What the record documents | What the record cannot establish alone |
|---|---|---|
| ClinicalTrials.gov record NCT05929066 | A completed phase 3 registry record in adults with obesity or overweight; the record documents design and endpoints, not an FDA approval. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| ClinicalTrials.gov record NCT04881760 | The registry companion to the 338-participant phase 2 publication, including protocol history and posted study documents. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| ClinicalTrials.gov pre-approval expanded-access record NCT07629401 | A registry entry for eligibility-limited pre-approval expanded access. It is not commercial approval, retail availability, ordinary prescribing, or a HealthRX service. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| FDA status statement for unapproved GLP-1 drugs | Documents that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
How HealthRX evaluated this question
ClinicalTrials.gov is a registry, not a pharmacy directory. Location modules can include sites for completed, active, or planned studies and can change after a record is posted. HealthRX reviewed the registry-level state field, record identifier, and snapshot date—not private eligibility information or unverified third-party trial listings.
For this page, HealthRX asked: (1) Is trial-registry status in Tennessee named in the protocol or publication? (2) Was it a prespecified endpoint, eligibility factor, subgroup, or only background context? (3) Is the record complete, current, and peer reviewed? (4) Does an FDA action or approved label exist? That sequence prevents a research observation from being rewritten as a product claim.
Evidence checks specific to this record
Source version
ClinicalTrials.gov records can change as recruitment, locations, outcomes, and completion dates are updated. Record the review date for trial-registry status in Tennessee, inspect the change history, and let the current primary record control over an older search snippet or copied summary.
Terminology discipline
Keep 'investigational,' 'registered,' 'completed,' 'published,' 'expanded access,' and 'FDA-approved' distinct. For trial-registry status in Tennessee, these terms describe different stages or pathways and should never be collapsed into the idea that a commercial treatment is available.
Eligibility versus evidence
Eligibility criteria define who could enter a study; they do not prove that each eligible group was adequately enrolled or separately analyzed. A careful review of trial-registry status in Tennessee distinguishes permitted enrollment from actual representation and prespecified analysis.
Regulatory checkpoint
Search for a controlling FDA action after reviewing trials and publications. For trial-registry status in Tennessee, a study completion date, peer-reviewed paper, company announcement, or expanded-access entry does not replace an approval letter and approved prescribing information.
Missing-data handling
Check participant flow, discontinuations, missing measurements, and the estimand used for analysis. For trial-registry status in Tennessee, a result based only on completers may answer a different question from an analysis that accounts for everyone randomized.
What remains unresolved
Federal approval and compounding status do not change by state. A Tennessee location in a study record is research metadata, not a retail listing, prescription pathway, price, insurance benefit, or HealthRX offering.
The source hierarchy also matters. An FDA action controls approval status. ClinicalTrials.gov controls the public registry record. A peer-reviewed report can describe study methods and observations. A press release, seller page, social post, search result, or anecdote cannot replace those sources.
What evidence could change the answer
Readers evaluating a registry record should check its current overall status, site status, eligibility criteria, last update date, sponsor, and official contact fields directly on ClinicalTrials.gov.
Any new result should be read with its protocol and statistical analysis plan. Important checks include enrollment, prespecified outcomes, follow-up duration, missing-data handling, multiplicity, participant flow, sponsor involvement, and whether the finding has undergone peer review and regulatory review.
Current federal and commercial status
Retatrutide remains investigational. No retatrutide product is FDA-approved for any indication or available through ordinary commercial prescription or retail sale. FDA states that retatrutide cannot be used in compounding under federal law. HealthRX does not offer it. FDA's current statement says retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. A ClinicalTrials.gov study or eligibility-limited expanded-access record is not commercial approval, ordinary prescribing, retail availability, or evidence that HealthRX offers the investigational substance.
Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.
Source selection and review method
HealthRX reviewed primary or primary-index sources current to 2026-08-09: ClinicalTrials.gov record NCT05929066; ClinicalTrials.gov record NCT04881760; ClinicalTrials.gov pre-approval expanded-access record NCT07629401; FDA status statement for unapproved GLP-1 drugs; 21 CFR 312.7, Promotion of investigational drugs. Sources were selected because they control regulatory status, register a study, or index a peer-reviewed clinical report. The review reports study design and evidence limits without reproducing promotional outcome claims or converting protocols into patient instructions.
Frequently asked questions
Does a study location mean retatrutide is available for prescription?
No. A ClinicalTrials.gov location is research metadata. It does not establish commercial supply, ordinary prescribing, pharmacy dispensing, insurance coverage, or eligibility for a study.
Can state law make compounded retatrutide permissible?
FDA states that retatrutide cannot be used in compounding under federal law. A state location does not change that federal status.
How current is the trial-registry status in Tennessee review?
HealthRX checked FDA, federal-regulation, publication, and ClinicalTrials.gov records on 2026-08-09. Registry locations and study statuses can change, so the linked primary record controls.
References
- ClinicalTrials.gov. TRIUMPH-1 registry record. 2026. https://clinicaltrials.gov/study/NCT05929066
- ClinicalTrials.gov. Phase 2 obesity-study registry record. 2026. https://clinicaltrials.gov/study/NCT04881760
- ClinicalTrials.gov. Pre-approval expanded-access registry record. 2026. https://clinicaltrials.gov/study/NCT07629401
- U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7